https://www.noxopharm.com/site/PDF/2021_4/NOXReleasesLatestNewsle...

https://www.noxopharm.com/site/PDF/2021_4/NOXReleasesLatestNewsletter

Noxopharm is aware of only two non-nucleotide STING agonists under development, intended to deliver a STING effect on a general basis but limited to cancer cells.  One is the compound, MAVU-104, a pre-clinical drug candidate under development by Seattle-based Mavupharma.16  Mavupharma was acquired this week by Abbvie.  The second drug candidate is Veyonda®.

Abbvie, a biopharmaceutical company with ~30,000 employees and a market cap of $102 Billion, paid an undisclosed sum for a pre-clinical compound.

Veyonda is already in the clinic and appears to selectively activate STING in humans - i.e. in cancer cells alone.  I am happy to hold until someone comes knocking on our door.